Wanbury Ltd
Wanbury Q1 FY27: Revenue ₹164.58 Cr, PAT ₹21.70 Cr
Q1 FY27 investor presentation: what the company reported on revenue, margins and projects.
Based on Wanbury Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q4FY26 Revenue from Operations: ₹164.58 Crore - Year-on-Year (YoY) change: +1% - Q4FY26 API Revenue: ₹144 Crore - YoY change: -4% - FY26 Total Revenue from Operations: ₹650.26 Crore - YoY change: +8% (from ₹599.51 Crore in FY25) - FY26 API Revenue: ₹574 Crore - YoY growth: 8% - FY26 Formulations Revenue: ₹76 Crore - Management Commentary notes a revenue decline in Q4 due to West Asia crisis impacting API exports in March but states growth expected from new product launches in Q4. EBITDA for Q4FY26: ₹30.06 Crore, with a year-on-year (YoY) growth of 12% - EBITDA Margin for Q4FY26: 18.3%, up by 173 basis points (BPS) YoY - Profit After Tax (PAT) for Q4FY26: ₹21.70 Crore, with YoY growth of 38% - PAT Margin for Q4FY26: 13.19%, up by 349 BPS YoY The presentation does not explicitly state a detailed margin outlook but notes increased EBITDA margins supported by operational efficiencies and product launch momentum (Page 29 Management Commentary).
From Wanbury Ltd's Q1 FY27 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
- Q4FY26 Revenue from Operations: ₹164.58 Crore
- Year-on-Year (YoY) change: +1%
- Q4FY26 API Revenue: ₹144 Crore
- YoY change: -4%
- FY26 Total Revenue from Operations: ₹650.26 Crore
- YoY change: +8% (from ₹599.51 Crore in FY25)
- FY26 API Revenue: ₹574 Crore
- YoY growth: 8%
- FY26 Formulations Revenue: ₹76 Crore
- Management Commentary notes a revenue decline in Q4 due to West Asia crisis impacting API exports in March but states growth expected from new product launches in Q4.
- Outlook:
2 more points management made on revenue & sales performance
Profitability & Margins
See what Wanbury Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Upcoming 1.5 MW solar energy project at Satara site to meet 70% of Patalganga site’s energy needs through renewable energy (Page 12).
- Brownfield expansion planned for operational scale-up and margin expansion (Page 5).
- Future reactor capacity potential at existing sites: 600 KL (current capacity 500 KL) indicating planned capacity expansion (Page 15).
- New anaesthetic molecule commercialized in Q4FY26, with a pipeline of 4 molecules planned for commercial launch each year from FY27 (Page 19).
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Wanbury Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Wanbury Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹162 Cr, net profit ₹16 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
Others in Pharmaceuticals & Biotechnology this season
- Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
- RPG Life Sciences Ltd (Q1 FY27)
Q1 FY27 Revenue from Operations: ₹195.7 crores, up 15.8% YoY (Q1 FY26: ₹168.9 crores) [Page 18] . Key concall takeaways from RPG Life Sciences Ltd's Q1 FY27…
- SMS Pharmaceuticals Ltd (Q1 FY27)
Q1FY27 revenue from operations: ₹207 crore, up 6% YoY (Page 6, 5) . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY27 earnings call — and how it…
- Symbiotec Pharmalab Ltd (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹218.2 crores, up 7% YoY from ₹203.2 crores in Q1 FY26 (Page 9). Key concall takeaways from Symbiotec Pharmalab…
Frequently Asked Questions
What were Wanbury Ltd Q1 FY27 results?
Q4FY26 Revenue from Operations: ₹164.58 Crore - Year-on-Year (YoY) change: +1% - Q4FY26 API Revenue: ₹144 Crore - YoY change: -4% - FY26 Total Revenue from Operations: ₹650.26 Crore - YoY change: +8% (from ₹599.51 Crore in FY25) - FY26 API Revenue: ₹574 Crore - YoY growth: 8% - FY26 Formulations Revenue: ₹76 Crore - Management Commentary notes a revenue decline in Q4 due to West Asia crisis impacting API exports in March but states growth expected from new product launches in Q4. EBITDA for Q4FY26: ₹30.06 Crore, with a year-on-year (YoY) growth of 12% - EBITDA Margin for Q4FY26: 18.3%, up by 173 basis points (BPS) YoY - Profit After Tax (PAT) for Q4FY26: ₹21.70 Crore, with YoY growth of 38% - PAT Margin for Q4FY26: 13.19%, up by 349 BPS YoY The presentation does not explicitly state a detailed margin outlook but notes increased EBITDA margins supported by operational efficiencies and product launch momentum (Page 29 Management Commentary).
What is Wanbury Ltd share price analysis?
Wanbury Ltd currently shows a neutral. The stock trades at a P/E of 13.1 with a market cap of ₹779 Cr. Investors should review the full earnings analysis for detailed insights.
Is Wanbury Ltd planning capital expenditure?
Upcoming 1.5 MW solar energy project at Satara site to meet 70% of Patalganga site’s energy needs through renewable energy (Page 12).
Keep Wanbury Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.